Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

FGFR3 has tumor suppressor properties in cells with epithelial phenotype.

Lafitte M, Moranvillier I, Garcia S, Peuchant E, Iovanna J, Rousseau B, Dubus P, Guyonnet-Dupérat V, Belleannée G, Ramos J, Bedel A, de Verneuil H, Moreau-Gaudry F, Dabernat S.

Mol Cancer. 2013 Jul 31;12:83. doi: 10.1186/1476-4598-12-83.

2.

FGFR3 stimulates stearoyl CoA desaturase 1 activity to promote bladder tumor growth.

Du X, Wang QR, Chan E, Merchant M, Liu J, French D, Ashkenazi A, Qing J.

Cancer Res. 2012 Nov 15;72(22):5843-55. doi: 10.1158/0008-5472.CAN-12-1329. Epub 2012 Sep 26.

4.

MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways.

Oneyama C, Ikeda J, Okuzaki D, Suzuki K, Kanou T, Shintani Y, Morii E, Okumura M, Aozasa K, Okada M.

Oncogene. 2011 Aug 11;30(32):3489-501. doi: 10.1038/onc.2011.63. Epub 2011 Mar 7.

PMID:
21383697
5.

Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.

Juanpere N, Agell L, Lorenzo M, de Muga S, López-Vilaró L, Murillo R, Mojal S, Serrano S, Lorente JA, Lloreta J, Hernández S.

Hum Pathol. 2012 Oct;43(10):1573-82. doi: 10.1016/j.humpath.2011.10.026. Epub 2012 Mar 12.

PMID:
22417847
6.

Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans.

Logié A, Dunois-Lardé C, Rosty C, Levrel O, Blanche M, Ribeiro A, Gasc JM, Jorcano J, Werner S, Sastre-Garau X, Thiery JP, Radvanyi F.

Hum Mol Genet. 2005 May 1;14(9):1153-60. Epub 2005 Mar 16.

PMID:
15772091
7.

Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations.

Ronchetti D, Greco A, Compasso S, Colombo G, Dell'Era P, Otsuki T, Lombardi L, Neri A.

Oncogene. 2001 Jun 14;20(27):3553-62.

8.

Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.

Chesi M, Brents LA, Ely SA, Bais C, Robbiani DF, Mesri EA, Kuehl WM, Bergsagel PL.

Blood. 2001 Feb 1;97(3):729-36.

9.

FGFR3 is a negative regulator of the expansion of pancreatic epithelial cells.

Arnaud-Dabernat S, Kritzik M, Kayali AG, Zhang YQ, Liu G, Ungles C, Sarvetnick N.

Diabetes. 2007 Jan;56(1):96-106.

10.

Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function.

Schniewind B, Groth S, Sebens Müerköster S, Sipos B, Schäfer H, Kalthoff H, Fändrich F, Ungefroren H.

Oncogene. 2007 Jul 19;26(33):4850-62. Epub 2007 Feb 12.

PMID:
17297450
11.

Chromosome 12, frequently deleted in human pancreatic cancer, may encode a tumor-suppressor gene that suppresses angiogenesis.

Yamanaka S, Sunamura M, Furukawa T, Sun L, Lefter LP, Abe T, Yatsuoka T, Fujimura H, Shibuya E, Kotobuki N, Oshimura M, Sakurada A, Sato M, Kondo T, Matsuno S, Horii A.

Lab Invest. 2004 Oct;84(10):1339-51.

12.

Fibroblast growth factor receptors-1 and -3 play distinct roles in the regulation of bladder cancer growth and metastasis: implications for therapeutic targeting.

Cheng T, Roth B, Choi W, Black PC, Dinney C, McConkey DJ.

PLoS One. 2013;8(2):e57284. doi: 10.1371/journal.pone.0057284. Epub 2013 Feb 26.

13.
14.
15.

Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.

Qing J, Du X, Chen Y, Chan P, Li H, Wu P, Marsters S, Stawicki S, Tien J, Totpal K, Ross S, Stinson S, Dornan D, French D, Wang QR, Stephan JP, Wu Y, Wiesmann C, Ashkenazi A.

J Clin Invest. 2009 May;119(5):1216-29. doi: 10.1172/JCI38017. Epub 2009 Apr 20.

16.

A positive FGFR3/FOXN1 feedback loop underlies benign skin keratosis versus squamous cell carcinoma formation in humans.

Mandinova A, Kolev V, Neel V, Hu B, Stonely W, Lieb J, Wu X, Colli C, Han R, Pazin MJ, Ostano P, Dummer R, Brissette JL, Dotto GP.

J Clin Invest. 2009 Oct;119(10):3127-37. doi: 10.1172/JCI38543. Erratum in: J Clin Invest. 2010 Feb;120(2):6455. Pazin, Mike [corrected to Pazin, Michael J].

17.

Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.

Zieger K, Dyrskjøt L, Wiuf C, Jensen JL, Andersen CL, Jensen KM, Ørntoft TF.

Clin Cancer Res. 2005 Nov 1;11(21):7709-19.

18.

Overexpression of fibroblast growth factor receptor 4 in high-grade pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma.

Motoda N, Matsuda Y, Onda M, Ishiwata T, Uchida E, Naito Z.

Int J Oncol. 2011 Jan;38(1):133-43.

PMID:
21109934
19.

Differential roles of fibroblast growth factor receptors (FGFR) 1, 2 and 3 in the regulation of S115 breast cancer cell growth.

Tarkkonen KM, Nilsson EM, Kähkönen TE, Dey JH, Heikkilä JE, Tuomela JM, Liu Q, Hynes NE, Härkönen PL.

PLoS One. 2012;7(11):e49970. doi: 10.1371/journal.pone.0049970. Epub 2012 Nov 21.

20.

Activating FGFR3 mutations cause mild hyperplasia in human skin, but are insufficient to drive benign or malignant skin tumors.

Duperret EK, Oh SJ, McNeal A, Prouty SM, Ridky TW.

Cell Cycle. 2014;13(10):1551-9. doi: 10.4161/cc.28492. Epub 2014 Mar 12.

Supplemental Content

Support Center